http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
-
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
-
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
-
Guardant Health (GH) Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
-
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
-
Guardant Health (GH) Announces 3.39M Share Offering at $26.77/sh
-
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
-
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Guardant Health (GH) Announces Tentative Date of FDA Advisory Panel Review of Shield Blood Test
-
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
-
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
-
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health (GH) to Appeal Federal District Court Verdict
-
Guardant Health to Appeal Federal District Court Verdict
-
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
-
Guardant Health to Participate in Upcoming November Investor Conferences
-
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
-
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
-
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
-
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
-
Guardant Health (GH) Receives Regulatory Approval in Japan for Guardant360 CDx as Companion Diagnostic to ENHERTU
-
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
-
Guardant Health (GH) Provides Update on COBRA Study, Restates Confidence in MRD Test
-
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
-
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
Guardant Health to Host Investor Day on September 7, 2023
-
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
-
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
-
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
-
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
-
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
-
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
-
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
-
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
-
Guardant Health Releases Inaugural ESG Report
-
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
-
Guardant Health Announces Additions to Leadership Team
-
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
-
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
-
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
-
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
-
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
-
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
-
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
-
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
